CXCR2在食管癌组织中的表达及其对食管癌细胞生物学行为的影响

doi:10.3969/j.issn.1004-616x.2024.01.009

Abstract

Abstract: OBJECTIVE: To investigate expression of the CXC receptor 2(CXCR2) in esophageal squamous cell carcinoma(ESCC) tissues and its impact on the biological behavior of esophageal cancer cells.METHODS: A total of 74 cases of surgically removed ESCC tissues were collected as the study group and 74 cases of paired adjacent normal esophageal tissues were collected as the control group. CXCR2 expression was detected by immunohistochemical staining, and the difference of CXCR2 expression level between the study and the control groups was compared, and the relationship between CXCR2 expression and clinicopathological characteristics was analyzed. The effects of CXCR2 antagonist SCH527123 on the biological behavior of esophageal cancer cells KYSE30 were examined by CCK-8 cell proliferation, plate colony formation, cell migration and invasion assay. RESULTS: The positive expression rate of CXCR2 in ESCC was 73.0%(54/74), which was significantly higher than the 13.5%(10/74) in the adjacent normal tissues(χ²=53.298, P=0.000). Significant differences were also detected in relation to the differentiation degree and lymph node metastasis of ESCC(χ²=5.515, P=0.019; χ²=7.320, P=0.007). However, the expression was not significantly related to gender, age, tumor location, gross classification of tumor, tumor diameter, depth of invasion, vessel emboli and nerve invasion(P>0.05). In the KYSE30 cells, application of the antagonist SCH527123 significantly inhibited their proliferation, migration, and invasion. CONCLUSION: CXCR2 expression was up regulated in ESCC tissues and was associated with poor prognosis of patients.CXCR2 antagonist SCH527123 inhibited the proliferation, migration, and invasion of esophageal cancer cells in vitro. CXCR2 may therefore be a molecular marker for molecular prediction and targeted therapy of esophageal cancer.

Key words: CXCR2, esophageal squamous cell carcinoma, clinical significance, pathological features, targeted therapy, biological behavior

CLC Number:

R979.1

HUANG Conggai, LIU Qing, ZHENG Shutao, LIU Tao, TAN Yiyi, PENG Tianyuan, CHEN Jiao, LU Xiaomei. Expression of CXCR2 in esophageal cancer tissues and its impact on biological behavior of esophageal cancer cells[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 53-57,65.

References

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
[2] XIA C F, DONG X S, LI H, et al. Cancer statistics in China and United States, 2022:profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5):584-590.
[3] ROGERS J E, SEWASTJANOW-SILVA M, WATERS R E, et al. Esophageal cancer:emerging therapeutics[J]. Expert Opin Ther Targets, 2022, 26(2):107-117.
[4] LAZENNEC G, RAJARATHNAM K, RICHMOND A. CXCR2chemokine receptor-a master regulator in cancer and physiology[J]. Trends Mol Med, 2024, 30(1):37-55.
[5] ZHANG Y L, CAO H J, HAN X, et al. Chemokine receptor CXCR-2 initiates atrial fibrillation by triggering monocyte mobilization in mice[J]. Hypertension, 2020, 76(2):381-392.
[6] PAWLUCZUK E,ŁUKASZEWICZ-ZAJĄC M, MROCZKO B.The role of chemokines in the development of gastric cancerdiagnostic and therapeutic implications[J]. Int J Mol Sci, 2020,21(22):8456.
[7] WU K, CUI L L, YANG Y, et al. Silencing of CXCR2 and CXCR7 protects against esophageal cancer[J]. Am J Transl Res, 2016, 8(8):3398-3408.
[8] SUI P, HU P P, ZHANG T H, et al. High expression of CXCR-2 correlates with lymph node metastasis and predicts unfavorable prognosis in resected esophageal carcinoma[J].Med Oncol, 2014, 31(2):809.
[9] 曹旬旬,费素娟.食管癌患者肿瘤组织CXCL5和CXCR2的表达与病情和预后的相关性分析[J].中华消化病与影像杂志:电子版, 2023, 13(5):299-304.
[10] 范玉宏,周海丰,范爽,等. CXCR-2在食管鳞癌组织中的表达及其与MMP-9、VEGF的相关性研究[J].癌变·畸变·突变, 2021, 33(3):225-229, 240.
[11] NISHI T, TAKEUCHI H, MATSUDA S, et al. CXCR2expression and postoperative complications affect long-term survival in patients with esophageal cancer[J]. World J Surg Oncol, 2015, 13:232.
[12] CHAPMAN R W, MINNICOZZI M, CELLY C S, et al. A novel,orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation[J]. J Pharmacol Exp Ther, 2007, 322(2):486-493.
[13] SHANG F M, LI J. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway[J]. Med Clin, 2019, 152(11):425-430.
[14] ZHANG R J, ROQUE D M, READER J, et al. Combined inhibition of IL-6 and IL-8 pathways suppresses ovarian cancer cell viability and migration and tumor growth[J]. Int J Oncol, 2022, 60(5):50.
[15] FU S L, CHEN X, LIN H J, et al. Inhibition of interleukin 8/C-X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells[J]. Int J Oncol, 2018,53(1):349-357.
[16] NING Y, LABONTE M J, ZHANG W, et al. The CXCR2antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models[J]. Mol Cancer Ther, 2012, 11(6):1353-1364.
[17] INFANGER D W, CHO Y, LOPEZ B S, et al. Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche[J]. Cancer Res, 2013, 73(23):7079-7089.
[18] YANG X Y, CHEN X J, ZHANG S S, et al. Collagen1-mediated CXCL1 secretion in tumor cells activates fibroblasts to promote radioresistance of esophageal cancer[J].Cell Rep, 2023, 42(10):113270.
[19] OGURA M, TAKEUCHI H, KAWAKUBO H, et al. Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma[J]. Surgery, 2013, 154(3):512-520.
[20] 隋萍.趋化因子受体CXCR-2在食管癌组织中的表达及与淋巴结转移对指导预后的临床意义[D].济南:山东大学,2014.

Expression of CXCR2 in esophageal cancer tissues and its impact on biological behavior of esophageal cancer cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LIU Ruixue, LI Desheng, ZHANG Liwei. Characteristics of serum lipidomics among Kazakhs with esophageal squamous cell carcinomas based on the UPLC-MS/MS method [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 21-28,34.
[2]	WANG Kefang, CHEN Yu, WU Chenyu, LIU Mei, WANG Lijie, TIAN Jianguang, ZHOU Xiaohui, XU Lan. Clinicopathological roles of IL-17A and estrogen receptors α, β in epithelial ovarian cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 42-47.
[3]	ZHENG Yaqi, ZHAO Ziting, PAN Deyuan, LIU Luxin, XU Xiue, LIAO Liandi, WANG Shaohong, LI Enmin, XU Liyan. The expression of tonsoku-like DNA repair protein in esophageal carcinoma and its effect on the proliferation of esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 412-419.
[4]	WANG Yinong, LIU Guozheng, XIE Guanchao, FENG Dan, LI Sai, CAI Yan, ZHANG Yu, WANG Mingrong, HAO Jiajie. Inhibitory effects of ANXA2 knockdown on malignant phenotype of esophageal squamous carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 445-451.
[5]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[6]	SHI Jianhong, CHEN Dingxiong, LU Xiaotong, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Inhibitory effect of ICG-001 on proliferation of esophageal squamous carcinoma cells and its molecular mechanisms [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 187-191,196.
[7]	FENG Dan, FAN Zhilu, WANG Yinong, LI Sai, GUO Jing, CAI Yan, ZHANG Yu, WEI Wenqiang, WANG Mingrong, HAO Jiajie. P4HA2 promotes proliferation of esophageal squamous carcinoma cells via activating the EGFR/AKT/S6 signaling pathway [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 87-94,101.
[8]	LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.
[9]	CUI Wenxuan, JIAO Wenjing, ZHAO Wei, DU Yanyan, TIAN Guo, ZHANG Jinyan, MA Ming. Clinical values of combined FIB, FAR and serum tumor markers in diagnosis and progression of ESCC patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 289-294,326.
[10]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[11]	YANG Xingxiao, ZHANG Xueyuan, ZOU Naiyi, SHAN Bao'en, MA Ming, ZHU Shuchai. Effects of HMGB1 silencing on migration, invasion and radiosensitivity of esophageal squamous cell carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 327-333.
[12]	YANG Liyan, LIU Zou, HAO Jiajie, ZHANG Yu, WANG Mingrong. Study on the mechanism of nucleo-plasma translocation of p62 protein in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 338-344.
[13]	CHANG Chen, YANG Liyan, CAI Hongqing, YUAN Qing, HAO Jiajie, WANG Mingrong. Expressions and clinical implications of SERPINE1 mRNA in esophageal squamous carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 245-249.
[14]	ZHENG Junwen, CHANG Chen, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Investigation on expression and function of NEDD4 in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 203-207,224.
[15]	JIAO Wenjing, GUO Xiujuan, SHAO Junguo, JIAO Wenpeng, ZHANG Jinyan. Relationships among blood cell ratios, clinicopathological characteristics and prognosis in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 213-217.